Safilens receives FDA approval

Safilens has obtained approval from the Food and Drug Administration (FDA) for the sale of its fusion 1day family of daily contact lenses in the US. 

The daily hydrogel lenses will be sold under the Deseyne brand.  

The American subsidiary Bruno Vision Care LCC carried out the classification and approval process, which lasted over six years. 

This milestone has made Safilens the first Italian company in the sector to register its own material – Vifilcon C (in Europe, Filcon IV), a new hydrogel material - in the US. 

‘This is a crucial achievement, especially for a manufacturer like Safilens that must be considered a minor player when compared to the giant multinationals active in this industry,’ remarked Daniele Bazzocchi, Safilens general manager.